The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients
Open accessAbstract
The widespread coronavirus SARS-CoV-2 has already infected over 4 million people worldwide, with a death toll over 280,000. Current treatment of COVID-19 patients relies mainly on antiviral drugs lopinavir/ritonavir, arbidol, and remdesivir, the anti-malarial drugs hydroxychloroquine and chloroquine, and traditional Chinese medicine. There are over 2,118 on-going clinical trials underway, but to date none of these drugs have consistently proven effective. Cathepsin L (CatL) is an endosomal cysteine protease. It mediates the cleavage of the S1 subunit of the coronavirus surface spike glycoprotein. This cleavage is necessary for coronavirus entry into human host cells, virus and host cell endosome membrane fusion, and viral RNA release for next round of replication. Here we summarize data regarding seven CatL-selective inhibitors that block coronavirus entry into cultured host cells and provide a mechanism to block SARS-CoV-2 infection in humans. Given the rapid growth of the SARS-CoV-2-positive population worldwide, ready-to-use CatL inhibitors should be explored as a treatment option. We identify ten US FDA-approved drugs that have CatL inhibitory activity. We provide evidence that supports the combined use of serine protease and CatL inhibitors as a possibly safer and more effective therapy than other available therapeutics to block coronavirus host cell entry and intracellular replication, without compromising the immune system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · cited 1×
“After the first patient was identified in December 2019 (Huang et al., 2020; Li et al., 2020), this virus spread rapidly from Wuhan to nearly all 34 provinces, municipalities, and special administrative regions in China and over 250 countries, territories, and areas around the globe (https://www.”
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Self-citationLu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
First case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Self-citationStructural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020) · Science · doi:10.1126/science.abb2762 · Cited by 5,040
Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany
Rothe, C., Schunk, M., Sothmann, P., Bretzel, G., Froeschl, G., Wallrauch, C., Zimmer, T., Thiel, V., Janke, C., Guggemos, W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001468 · Cited by 4,144
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
Chan, J. F.-W., Kok, K.-H., Zhu, Z., Chu, H., To, K. K.-W., Yuan, S., & Yuen, K.-Y. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1719902 · Cited by 3,059
Structure, Function, and Evolution of Coronavirus Spike Proteins
Li, F. (2016) · Annual Review of Virology · doi:10.1146/annurev-virology-110615-042301 · Cited by 2,740
Compassionate Use of Remdesivir for Patients with Severe Covid-19
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F.-X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007016 · Cited by 2,737
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,662
HCA Lung Biological Network, Sungnak, W., Huang, N., Bécavin, C., Berg, M., Queen, R., Litvinukova, M., Talavera-López, C., Maatz, H., Reichart, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0868-6 · Cited by 2,501 · cited 1×
“Second, SARS-CoV-2 infection not only infects the respiratory tract, but also affects other organs in which not all cells express TMPRSS2 (Hoffmann, Kleine-Weber et al., 2020; Sungnak et al., 2020).”
Zou, X., Chen, K., Zou, J., Han, P., Hao, J., & Han, Z. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0754-0 · Cited by 2,287
F. T. Z. H. O. W. U. N. C. M. A. R. T., Jin, Y.-H., Cai, L., Cheng, Z.-S., Cheng, H., Deng, T., Fan, Y.-P., Fang, C., Huang, D., Huang, L.-Q., et al. (2020) · Military Medical Research · doi:10.1186/s40779-020-0233-6 · Cited by 2,254
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,811
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. M. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,645
COVID-19 infection: the perspectives on immune responses
Shi, Y., Wang, Y., Shao, C., Huang, J., Gan, J., Huang, X., Bucci, E., Piacentini, M., Ippolito, G., & Melino, G. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-020-0530-3 · Cited by 1,594
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,416
Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein
Belouzard, S., Millet, J. K., Licitra, B. N., & Whittaker, G. R. (2012) · Viruses · doi:10.3390/v4061011 · Cited by 1,368
Glowacka, I., Bertram, S., Müller, M. A., Allen, P., Soilleux, E., Pfefferle, S., Steffen, I., Tsegaye, T. S., He, Y., Gnirss, K., et al. (2011) · Journal of Virology · doi:10.1128/jvi.02232-10 · Cited by 1,108
Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry
Simmons, G., Gosalia, D. N., Rennekamp, A. J., Reeves, J. D., Diamond, S. L., & Bates, P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505577102 · Cited by 1,052
Song, W., Gui, M., Wang, X., & Xiang, Y. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007236 · Cited by 834
EMERGING ROLES FOR CYSTEINE PROTEASES IN HUMAN BIOLOGY
Chapman, H. A., Riese, R. J., & Shi, G.-P. (1997) · Annual Review of Physiology · doi:10.1146/annurev.physiol.59.1.63 · Cited by 786
Self-citationMorse, J. S., Lalonde, T., Xu, S., & Liu, W. R. (2020) · ChemBioChem · doi:10.1002/cbic.202000047 · Cited by 776
Millet, J. K., & Whittaker, G. R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407087111 · Cited by 698
Cathepsin L: Critical Role in Ii Degradation and CD4 T Cell Selection in the Thymus
Nakagawa, T., Roth, W., Wong, P., Nelson, A., Farr, A., Deussing, J., Villadangos, J. A., Ploegh, H., Peters, C., & Rudensky, A. Y. (1998) · Science · doi:10.1126/science.280.5362.450 · Cited by 674
The endosomal-lysosomal system: from acidification and cargo sorting to neurodegeneration
Hu, Y.-B., Dammer, E. B., Ren, R.-J., & Wang, G. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0041-1 · Cited by 666
Protease inhibitors targeting coronavirus and filovirus entry
Zhou, Y., Vedantham, P., Lu, K., Agudelo, J., Carrion, R., Nunneley, J. W., Barnard, D., Pöhlmann, S., McKerrow, J. H., Renslo, A. R., et al. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.01.011 · Cited by 583
Wang, Z., Chen, X., Lu, Y., Chen, F., & Zhang, W. (2020) · BioScience Trends · doi:10.5582/bst.2020.01030 · Cited by 544
Riese, R. J., Wolf, P. R., Brömme, D., Natkin, L. R., Villadangos, J. A., Ploegh, H. L., & Chapman, H. A. (1996) · Immunity · doi:10.1016/s1074-7613(00)80249-6 · Cited by 535
Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development
Shi, G.-P., Villadangos, J. A., Dranoff, G., Small, C., Gu, L., Haley, K. J., Riese, R., Ploegh, H. L., & Chapman, H. A. (1999) · Immunity · doi:10.1016/s1074-7613(00)80020-5 · Cited by 524
Self-citationKawase, M., Shirato, K., van der Hoek, L., Taguchi, F., & Matsuyama, S. (2012) · Journal of Virology · doi:10.1128/jvi.00094-12 · Cited by 515
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
Hoffmann, M., Schroeder, S., Kleine-Weber, H., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00754-20 · Cited by 486
Mechanism of action of hydroxychloroquine as an antirheumatic drug
Fox, R. I. (1993) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(10)80012-5 · Cited by 430
Reducing mortality from 2019-nCoV: host-directed therapies should be an option.
Zumla, A., Hui, D. S., Azhar, E. I., Memish, Z. A., & Maeurer, M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30305-6 · Cited by 429
Simmons, G., Zmora, P., Gierer, S., Heurich, A., & Pöhlmann, S. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.028 · Cited by 413
Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection
Engel, J. C., Doyle, P. S., Hsieh, I., & McKerrow, J. H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.4.725 · Cited by 392
Rice, T. W., Rubinson, L., Uyeki, T. M., Vaughn, F. L., John, B. B., Miller, R. R., Higgs, E., Randolph, A. G., Smoot, B. E., & Thompson, B. T. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e3182416f23 · Cited by 391 · cited 3×
“Bacterial superinfection commonly complicates viral pneumonitis, particularly in patients who require endotracheal intubation (Chertow & Memoli, 2013; Rice et al., 2012).”
InfluentialBacterial Coinfection in Influenza: A Grand Rounds Review
Chertow, D. S., & Memoli, M. J. (2013) · JAMA · doi:10.1001/jama.2012.194139 · Cited by 390
Al-Bari, M. A. A. (2017) · Pharmacology Research & Perspectives · doi:10.1002/prp2.293 · Cited by 382
Goulet, B., Baruch, A., Moon, N.-S., Poirier, M., Sansregret, L. L., Erickson, A., Bogyo, M., & Nepveu, A. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00209-6 · Cited by 369
Secondary attack rate and superspreading events for SARS-CoV-2
Liu, Y., Eggo, R. M., & Kucharski, A. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30462-1 · Cited by 350 · cited 1×
“The genomic sequence of this novel coronavirus shares 82% identity with that of SARS-CoV Tor2 (AY274119) (Chan et al., 2020; Morse, Lalonde, Xu, & Liu, 2020).”
Bertram, S., Dijkman, R., Habjan, M., Heurich, A., Gierer, S., Glowacka, I., Welsch, K., Winkler, M., Schneider, H., Hofmann-Winkler, H., et al. (2013) · Journal of Virology · doi:10.1128/jvi.03372-12 · Cited by 350
Bosch, B. J., Bartelink, W., & Rottier, P. J. M. (2008) · Journal of Virology · doi:10.1128/jvi.00415-08 · Cited by 315
Josset, L., Menachery, V. D., Gralinski, L. E., Agnihothram, S., Sova, P., Carter, V. S., Yount, B. L., Graham, R. L., Baric, R. S., & Katze, M. G. (2013) · mBio · doi:10.1128/mbio.00165-13 · Cited by 293
Zhou, N., Pan, T., Zhang, J., Li, Q., Zhang, X., Bai, C., Huang, F., Peng, T., Zhang, J., Liu, C., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.716100 · Cited by 286
The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
Shang, W., Yang, Y., Rao, Y., & Rao, X. (2020) · npj Vaccines · doi:10.1038/s41541-020-0170-0 · Cited by 275
Wosen, J. E., Mukhopadhyay, D., Macaubas, C., & Mellins, E. D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02144 · Cited by 237
Tang, T.-T., Lv, L.-L., Pan, M.-M., Wen, Y., Wang, B., Li, Z.-L., Wu, M., Wang, F.-M., Crowley, S. D., & Liu, B.-C. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0378-3 · Cited by 212
Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials
Liu, C.-L., Guo, J., Zhang, X., Sukhova, G. K., Libby, P., & Shi, G.-P. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0002-3 · Cited by 210
Self-citationCathepsin L Regulates CD4+ T Cell Selection Independently of Its Effect on Invariant Chain
Honey, K., Nakagawa, T., Peters, C., & Rudensky, A. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011904 · Cited by 202
Chloroquine cardiomyopathy – a review of the literature
Tönnesmann, E., Kandolf, R., & Lewalter, T. (2013) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2013.780078 · Cited by 193
Menachery, V. D., Schäfer, A., Burnum-Johnson, K. E., Mitchell, H. D., Eisfeld, A. J., Walters, K. B., Nicora, C. D., Purvine, S. O., Casey, C. P., Monroe, M. E., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706928115 · Cited by 192
A Cysteine Protease Inhibitor Cures Chagas' Disease in an Immunodeficient-Mouse Model of Infection
Doyle, P. S., Zhou, Y. M., Engel, J. C., & McKerrow, J. H. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00436-07 · Cited by 187
Adedeji, A. O., Severson, W., Jonsson, C., Singh, K., Weiss, S. R., & Sarafianos, S. G. (2013) · Journal of Virology · doi:10.1128/jvi.00998-13 · Cited by 183
Khamitov, R. A., Loginova, S. I., Николаевна, Щ. В., Borisevich, S. V., Maksimov, V. A., & Shuster, A. M. (2008) · PubMed · Cited by 171
Liu, J., Wu, P., Gao, F., Qi, J., Kawana‐Tachikawa, A., Xie, J., Vavricka, C. J., Iwamoto, A., Li, T., & Gao, G. F. (2010) · Journal of Virology · doi:10.1128/jvi.01464-10 · Cited by 148
Haviernik, J., Štefánik, M., Fojtíková, M., Kali, S., Tordo, N., Rudolf, I., Hubálek, Z., Eyer, L., & Růžek, D. (2018) · Viruses · doi:10.3390/v10040184 · Cited by 140
Wang, S., Guo, F., Liu, K., Wang, H., Rao, S., Yang, P., & Jiang, C. (2008) · Virus Research · doi:10.1016/j.virusres.2008.03.004 · Cited by 139
Meyer, D., Sielaff, F., Hammami, M., Böttcher‐Friebertshäuser, E., Garten, W., & Steinmetzer, T. (2013) · Biochemical Journal · doi:10.1042/bj20130101 · Cited by 130
Cathepsin S Controls MHC Class II-Mediated Antigen Presentation by Epithelial Cells In Vivo
Beers, C., Burich, A., Kleijmeer, M. J., Griffith, J. M., Wong, P., & Rudensky, A. Y. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1205 · Cited by 126
Gereke, M., Jung, S., Buer, J., & Bruder, D. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200804-592oc · Cited by 121
Elshabrawy, H. A., Fan, J.-L., Haddad, C., Ratia, K. M., Broder, C. C., Caffrey, M. S., & Prabhakar, B. S. (2014) · Journal of Virology · doi:10.1128/jvi.03050-13 · Cited by 117
Chu, V. C., McElroy, L. J., Chu, V., Bauman, B. E., & Whittaker, G. R. (2006) · Journal of Virology · doi:10.1128/jvi.80.7.3180-3188.2006 · Cited by 113
A Review of Small Molecule Inhibitors and Functional Probes of Human Cathepsin L
Dana, D., & Pathak, S. K. (2020) · Molecules · doi:10.3390/molecules25030698 · Cited by 108
Cathepsin B and L inhibitors: a patent review (2010 - present)
Li, Y.-Y., Fang, J. Y., & Ao, G. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1272572 · Cited by 104
Corbett, A., Lim, M. L., & Kashuba, A. D. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a363 · Cited by 100
Differential Regulation of Cathepsin S and Cathepsin L in Interferon γ–treated Macrophages
Beers, C., Honey, K., Fink, S. L., Forbush, K. A., & Rudensky, A. Y. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20020978 · Cited by 99
Gonçalves, D. A. P., Silveira, W. A., Lira, E. C., Graça, F. A., Paula-Gomes, S., Zanon, N. M., Kettelhut, Í. D. C., & Navegantes, L. C. C. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00188.2011 · Cited by 95
Porotto, M., Orefice, G., Yokoyama, C. C., Mungall, B. A., Realubit, R. B., Sganga, M. L., Aljofan, M., Whitt, M. A., Glickman, J. F., & Moscona, A. (2009) · Journal of Virology · doi:10.1128/jvi.00164-09 · Cited by 93
Corbière, V., Dirix, V., Norrenberg, S., Cappello, M., Remmelink, M., & Mascart, F. (2011) · Respiratory Research · doi:10.1186/1465-9921-12-15 · Cited by 74
Matsuyama, S., Shirato, K., Kawase, M., et al. (2018) · Journal of Virology · doi:10.1128/jvi.00683-18 · Cited by 70
Crossland, H., Constantin‐Teodosiu, D., Greenhaff, P. L., & Gardiner, S. M. (2010) · The Journal of Physiology · doi:10.1113/jphysiol.2009.183699 · Cited by 61
on behalf of the TACTIC Investigative Team, Ramsey, M. L., Nuttall, J., & Hart, P. A. (2019) · Trials · doi:10.1186/s13063-019-3606-y · Cited by 57
Differential Roles of Cysteinyl Cathepsins in TGF-β Signaling and Tissue Fibrosis
Zhang, X., Zhou, Y., Yu, X., Huang, Q. M., Fang, W., Li, J., Bonventre, J. V., Sukhova, G. K., Libby, P., & Shi, G. (2019) · iScience · doi:10.1016/j.isci.2019.08.014 · Cited by 52
Self-citationSecondary Household Transmission of SARS, Singapore
Goh, D. L. M., Lee, B. W., Chia, K. S., Heng, B. H., Chen, M. I.-C., Ma, S., & Tan, C. C. (2004) · Emerging infectious diseases · doi:10.3201/eid1002.030676 · Cited by 51
Astaxanthin intake attenuates muscle atrophy caused by immobilization in rats
Shibaguchi, T., Yamaguchi, Y., Miyaji, N., Yoshihara, T., Naito, H., Goto, K., Ohmori, D., Yoshioka, T., & Sugiura, T. (2016) · Physiological Reports · doi:10.14814/phy2.12885 · Cited by 46 · cited 1×
“Astaxanthin, a potential immunomodulatory antioxidant agent, can suppress CatL activity in both Syrianhamster embryo cells and muscle cells (Shibaguchi et al., 2016).”
BackgroundEndosomal acidification and cathepsin L activity is required for calicivirus replication
Shivanna, V., Kim, Y., & Chang, K. (2014) · Virology · doi:10.1016/j.virol.2014.07.025 · Cited by 41
Fang, W., Deng, Z., Benadjaoud, F., Yang, C., & Shi, G.-P. (2020) · Translational Research · doi:10.1016/j.trsl.2020.04.011 · Cited by 40
Self-citationTransmissibility of MERS-CoV Infection in Closed Setting, Riyadh, Saudi Arabia, 2015
Kerkhove, M. D. V., Alaswad, S., Assiri, A. M., Perera, R. A. P. M., Peiris, M. J. S., Bushra, H. E. E., & BinSaeed, A. A. (2019) · Emerging infectious diseases · doi:10.3201/eid2510.190130 · Cited by 35
Yang, J., James, E. A., Roti, M., Huston, L., Gebe, J. A., & Kwok, W. W. (2008) · International Immunology · doi:10.1093/intimm/dxn124 · Cited by 30
Identification and synthesis of a unique thiocarbazate cathepsin L inhibitor
Myers, M. C., Shah, P. P., Diamond, S. L., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.10.107 · Cited by 23
2019 update of the EULAR recommendations for the management of SLE: don't forget chloroquine
Figueroa‐Parra, G., Gamboa-Alonso, C. M., De-Leon-Ibarra, A. L., & Galarza-Delgado, D. Á. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215716 · Cited by 9
Cited by
Ciotti, M., Ciccozzi, M., Terrinoni, A., Jiang, W.-C., Wang, C.-B., & Bernardini, S. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1783198 · Cited by 1,514
Zhao, M.-M., Yang, W.-L., Yang, F.-Y., Zhang, L., Huang, W.-J., Hou, W., Fan, C.-F., Jin, R.-H., Feng, Y.-M., Wang, Y.-C., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00558-8 · Cited by 515
Multi-organ proteomic landscape of COVID-19 autopsies
Nie, X., Qian, L., Sun, R., Huang, B., Dong, X., Xiao, Q., Zhang, Q., Lu, T., Yue, L., Chen, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.004 · Cited by 408
Sacco, M. D., Ma, C., Lagarias, P., Gao, A., Townsend, J. A., Meng, X., Dube, P., Zhang, X., Hu, Y., Kitamura, N., et al. (2020) · Science Advances · doi:10.1126/sciadv.abe0751 · Cited by 385
TMPRSS2 expression dictates the entry route used by SARS‐CoV‐2 to infect host cells
Koch, J., Uckeley, Z. M., Doldan, P., Stanifer, M., Boulant, S., & Lozach, P. (2021) · The EMBO Journal · doi:10.15252/embj.2021107821 · Cited by 355
Metadata
- Authors
- Liu, T., Luo, S., Libby, P., & Shi, G.-P.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 213
- Pages
- 107587
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W3032297724
- Cited by
- 273
- References
- 90
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.